PRL3 modulates different signaling pathways involving p53, MAPK, protein kinase B (PKB, also known as AKT), mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3), FAK, and vascular endothelial growth factor (VEGF), hence positively acting on tumor cell proliferation and aggressiveness [120]. Here, STAT3 is linked to neoplasm.